Greetings from Lambda Therapeutic Research Ltd.!

I hope you and your loved ones are in the best of health.

Since the onset of the pandemic, we have left no stone unturned to ensure business continuity while safeguarding the health and welfare of our volunteers and employees. Our stringent safety policies continue to be successfully enabled by an exclusive cross-functional COVID-19 Safety Committee. These policies include the execution of several actions like Safety-focused Infrastructure Rearrangement, Immunization of Employees involved in Studies, Micro-logistic Arrangement, Enhanced Sanitisation of the facilities, and Multi- tasking Manpower Planning.

However, we remain vigilant, as the pandemic continues to evolve across the world. We are ready to enable prompt corporate governance policies as well as strategic and operational adaptions to fulfil the delivery time and quality commitments of every study.

A recent testament to our unfailing commitment to our clientele is the successful execution of a complex MAb study amidst the pandemic, which involved a large sample size of 234 volunteers. This study had a duration of 9 months, demanding stringent safety criteria, close monitoring of subjects and subject follow-up for almost a year, which in the current circumstances, is a challenging task.

As the world slowly but steadily recovers from the pandemic, health and medicine have become a top priority. As one of the world’s leading CROs, we are ready to fulfil our role and responsibilities in humanity's quest to safeguard life, working hand in hand with leading pharmaceutical organisations across the globe.

Wishing you abundant health and success, I assure you the very best of our services, always.

Stay safe.

Warm Regards,
Bindi Chudgar